

Annex G

EP 941 – Amendment A

1. A pharmaceutical composition comprising a liposome within which RNA encoding an immunogen of interest is encapsulated, wherein the liposome comprises at least one lipid which includes a polyethylene glycol moiety, such that polyethylene glycol is present on the liposome's exterior, wherein the average molecular mass of the polyethylene glycol is between 1kDa and 3kDa, wherein the pharmaceutical composition includes a Tris buffer, wherein the liposome comprises a lipid with a cationic head group and a lipid with a zwitterionic head group, and wherein the liposome is formed from a mixture of lipids, wherein the proportion of those lipids which are PEGylated is less than 10 mol% of the total amount of lipids, and wherein the remainder is made of 35-50 mol% cholesterol, 30-70 mol% cationic lipid and 5-15 mol% DSPC.

~~3. — The pharmaceutical composition of any preceding claim, wherein the liposome comprises a lipid with a cationic head group.~~

~~4. — The pharmaceutical composition of any preceding claim, wherein the liposome comprises a lipid with a zwitterionic head group.~~

*Claims not shown above remain as granted (subject to renumbering of claims and of cross-referenced claims).*

**Annex H**

**EP 941 – Amendment B**

1. A pharmaceutical composition comprising a liposome within which RNA encoding an immunogen of interest is encapsulated, wherein the liposome comprises at least one lipid which includes a polyethylene glycol moiety, such that polyethylene glycol is present on the liposome's exterior, wherein the average molecular mass of the polyethylene glycol is between 1kDa and 3kDa, wherein the pharmaceutical composition includes a Tris buffer, wherein the liposome comprises a lipid with a cationic head group and a lipid with a zwitterionic head group, and wherein the liposome is formed from a mixture of lipids, wherein 2 mol% of the total lipid is a PEG-DMG, and wherein the remainder is made of 35-50 mol% cholesterol, 30-70 mol% cationic lipid and 5-15 mol% DSPC.

~~3. — The pharmaceutical composition of any preceding claim, wherein the liposome comprises a lipid with a cationic head group.~~

~~4. — The pharmaceutical composition of any preceding claim, wherein the liposome comprises a lipid with a zwitterionic head group.~~

*Claims not shown above remain as granted (subject to renumbering of claims and of cross-referenced claims).*